Management of Rheumatoid Arthritis

QUESTION

What is the cornerstone of pharmacologic treatment in early rheumatoid arthritis?

ANSWER

Disease-modifying antirheumatic drugs (DMARDs), primarily methotrexate, are the cornerstone of early RA treatment to control disease activity and prevent joint damage.

QUESTION

Name two conventional synthetic DMARDs commonly used in RA management.

ANSWER

Methotrexate and sulfasalazine are two commonly used conventional synthetic DMARDs in RA.

QUESTION

When should biologic DMARDs be considered in RA treatment?

ANSWER

Biologic DMARDs are considered when patients have an inadequate response to at least 3-6 months of methotrexate therapy or have high disease activity despite conventional treatment.

QUESTION

List three classes of biologic agents used in RA management.

ANSWER

Tumor necrosis factor (TNF) inhibitors (e.g., etanercept), interleukin-6 receptor antagonists (e.g., tocilizumab), and B-cell depleting agents (e.g., rituximab).

QUESTION

What is the primary goal of RA treatment in the modern management approach?

ANSWER

To achieve clinical remission or low disease activity, prevent joint damage, and maintain functional status.

Master all 22 flashcards

Treatment strategies, DMARDs, biologics, and monitoring for RA patients at various stages.

TreatmentDMARDsmonitoringrheumatologybiologics

22 Cardsmedicine

What You'll Gain

Mastering this deck provides a comprehensive understanding of RA management, enabling clinicians to formulate effective, stage-specific treatment plans, monitor therapy response accurately, and minimize complications, ultimately improving patient outcomes.

ℹ️ Educational Use Only: This flashcard deck is created by usersof our platform for their educational and study purposes. The content is not intended as medical advice, diagnosis, or treatment guidance. Always consult qualified healthcare professionals for medical decisions and verify information with authoritative medical sources.

Flashcards Preview

Showing 20 of 22 cardsSample view

#	Front	Back	Hint
1	What is the cornerstone of pharmacologic treatment in early rheumatoid arthritis?	Disease-modifying antirheumatic drugs (DMARDs), primarily methotrexate, are the cornerstone of early RA treatment to control disease activity and prevent joint damage.	Think of DMARDs as the 'disease-modifying foundation' in RA.
2	Name two conventional synthetic DMARDs commonly used in RA management.	Methotrexate and sulfasalazine are two commonly used conventional synthetic DMARDs in RA.	Methotrexate is often first-line; think 'Meth' as a cornerstone drug.
3	When should biologic DMARDs be considered in RA treatment?	Biologic DMARDs are considered when patients have an inadequate response to at least 3-6 months of methotrexate therapy or have high disease activity despite conventional treatment.	Biologics are for refractory or severe cases after conventional DMARDs fail.
4	List three classes of biologic agents used in RA management.	Tumor necrosis factor (TNF) inhibitors (e.g., etanercept), interleukin-6 receptor antagonists (e.g., tocilizumab), and B-cell depleting agents (e.g., rituximab).	Biologics target specific immune pathways; remember 'TIB'—TNF, IL-6, B-cells.
5	What is the primary goal of RA treatment in the modern management approach?	To achieve clinical remission or low disease activity, prevent joint damage, and maintain functional status.	Think 'remission' as the ultimate target.
6	Name a common non-pharmacologic intervention for RA patients.	Physical therapy and occupational therapy to maintain joint function and reduce disability.	Beyond drugs, therapy helps 'move' with RA.
7	What monitoring parameters are essential when a patient is on methotrexate therapy?	Regular liver function tests, complete blood count, and renal function tests to monitor for hepatotoxicity, myelosuppression, and nephrotoxicity.	Liver, blood counts, kidneys—monitor these 'L-B-K' parameters.
8	Why is folic acid supplementation recommended for patients on methotrexate?	To reduce methotrexate-associated side effects such as mucositis, hepatotoxicity, and hematologic abnormalities.	Folic acid counteracts some of methotrexate's toxicity.
9	What are the indications for starting corticosteroids in RA management?	For acute flares, bridging therapy until DMARDs take effect, or in patients with high disease activity requiring rapid symptom control.	Steroids act quickly but are used short-term due to side effects.
10	What are common adverse effects associated with biologic DMARDs?	Increased risk of infections, infusion reactions, potential reactivation of latent tuberculosis, and rare demyelinating disease.	Monitor patients closely for infections.
11	How often should RA disease activity be assessed after initiating therapy?	Every 3 to 6 months, using tools like DAS28 (Disease Activity Score in 28 joints) to guide treatment adjustments.	Regular assessment ensures timely treatment modifications.
12	What is the role of imaging in monitoring RA progression?	X-rays, ultrasound, or MRI help detect joint erosion and synovitis progression, guiding treatment decisions.	Imaging reveals structural damage and inflammation.
13	Name a major complication of uncontrolled RA.	Joint destruction leading to deformity, and extra-articular manifestations such as rheumatoid nodules, lung involvement, or vasculitis.	Uncontrolled RA damages more than joints.
14	What is the significance of achieving remission in RA?	Remission reduces joint damage, preserves function, and improves quality of life; it is the primary treatment goal.	Aim for 'zero' disease activity.
15	Describe the concept of 'treat-to-target' in RA management.	A strategy where treatment is adjusted regularly with the goal of reaching and maintaining remission or low disease activity.	Treat-to-target emphasizes proactive management.
16	What modifications are recommended for RA patients with comorbid cardiovascular disease?	Use of low-dose corticosteroids cautiously, control of lipid levels, encourage smoking cessation, and promote physical activity, all while managing RA effectively.	Manage both RA and CV risks simultaneously.
17	Name a key factor influencing the choice between conventional and biologic DMARDs.	Disease severity, response to prior therapy, presence of comorbidities, and patient preference.	Tailor therapy based on individual patient factors.
18	What is the significance of anti-CCP antibodies in RA?	Anti-cyclic citrullinated peptide (anti-CCP) antibodies are specific markers that predict more aggressive disease and joint damage.	Anti-CCP positivity indicates a more severe RA course.
19	How does patient adherence influence RA treatment outcomes?	High adherence improves disease control, reduces flare frequency, and prevents joint damage; non-adherence can lead to treatment failure.	Adherence is key to success.
20	What is the typical first-line biologic agent used in RA?	Tumor necrosis factor (TNF) inhibitors such as etanercept or infliximab are often first-line biologics.	TNF inhibitors are the 'go-to' biologics initially.

Note: This preview shows only the first 20 cards. The complete deck contains 22 total cards. Start studying to access all flashcards.

Master all 22 flashcards

More Flashcard Decks

Explore other decks you might find helpful

Preventive Eye Care and Public Health

32 cards

Emergency Eye Care and Trauma Management

29 cards

Cell Structure and Organelles

28 cards

Basic Plant Anatomy and Structure

28 cards

Boost Flashcards

Management of Rheumatoid Arthritis

QUESTION

What is the cornerstone of pharmacologic treatment in early rheumatoid arthritis?

ANSWER

Disease-modifying antirheumatic drugs (DMARDs), primarily methotrexate, are the cornerstone of early RA treatment to control disease activity and prevent joint damage.

QUESTION

Name two conventional synthetic DMARDs commonly used in RA management.

ANSWER

Methotrexate and sulfasalazine are two commonly used conventional synthetic DMARDs in RA.

QUESTION

When should biologic DMARDs be considered in RA treatment?

ANSWER

Biologic DMARDs are considered when patients have an inadequate response to at least 3-6 months of methotrexate therapy or have high disease activity despite conventional treatment.

QUESTION

List three classes of biologic agents used in RA management.

ANSWER

Tumor necrosis factor (TNF) inhibitors (e.g., etanercept), interleukin-6 receptor antagonists (e.g., tocilizumab), and B-cell depleting agents (e.g., rituximab).

QUESTION

What is the primary goal of RA treatment in the modern management approach?

ANSWER

To achieve clinical remission or low disease activity, prevent joint damage, and maintain functional status.

Master all 22 flashcards

Treatment strategies, DMARDs, biologics, and monitoring for RA patients at various stages.

TreatmentDMARDsmonitoringrheumatologybiologics

22 Cardsmedicine

What You'll Gain

Flashcards Preview

Showing 20 of 22 cardsSample view

#	Front	Back	Hint
1	What is the cornerstone of pharmacologic treatment in early rheumatoid arthritis?	Disease-modifying antirheumatic drugs (DMARDs), primarily methotrexate, are the cornerstone of early RA treatment to control disease activity and prevent joint damage.	Think of DMARDs as the 'disease-modifying foundation' in RA.
2	Name two conventional synthetic DMARDs commonly used in RA management.	Methotrexate and sulfasalazine are two commonly used conventional synthetic DMARDs in RA.	Methotrexate is often first-line; think 'Meth' as a cornerstone drug.
3	When should biologic DMARDs be considered in RA treatment?	Biologic DMARDs are considered when patients have an inadequate response to at least 3-6 months of methotrexate therapy or have high disease activity despite conventional treatment.	Biologics are for refractory or severe cases after conventional DMARDs fail.
4	List three classes of biologic agents used in RA management.	Tumor necrosis factor (TNF) inhibitors (e.g., etanercept), interleukin-6 receptor antagonists (e.g., tocilizumab), and B-cell depleting agents (e.g., rituximab).	Biologics target specific immune pathways; remember 'TIB'—TNF, IL-6, B-cells.
5	What is the primary goal of RA treatment in the modern management approach?	To achieve clinical remission or low disease activity, prevent joint damage, and maintain functional status.	Think 'remission' as the ultimate target.
6	Name a common non-pharmacologic intervention for RA patients.	Physical therapy and occupational therapy to maintain joint function and reduce disability.	Beyond drugs, therapy helps 'move' with RA.
7	What monitoring parameters are essential when a patient is on methotrexate therapy?	Regular liver function tests, complete blood count, and renal function tests to monitor for hepatotoxicity, myelosuppression, and nephrotoxicity.	Liver, blood counts, kidneys—monitor these 'L-B-K' parameters.
8	Why is folic acid supplementation recommended for patients on methotrexate?	To reduce methotrexate-associated side effects such as mucositis, hepatotoxicity, and hematologic abnormalities.	Folic acid counteracts some of methotrexate's toxicity.
9	What are the indications for starting corticosteroids in RA management?	For acute flares, bridging therapy until DMARDs take effect, or in patients with high disease activity requiring rapid symptom control.	Steroids act quickly but are used short-term due to side effects.
10	What are common adverse effects associated with biologic DMARDs?	Increased risk of infections, infusion reactions, potential reactivation of latent tuberculosis, and rare demyelinating disease.	Monitor patients closely for infections.
11	How often should RA disease activity be assessed after initiating therapy?	Every 3 to 6 months, using tools like DAS28 (Disease Activity Score in 28 joints) to guide treatment adjustments.	Regular assessment ensures timely treatment modifications.
12	What is the role of imaging in monitoring RA progression?	X-rays, ultrasound, or MRI help detect joint erosion and synovitis progression, guiding treatment decisions.	Imaging reveals structural damage and inflammation.
13	Name a major complication of uncontrolled RA.	Joint destruction leading to deformity, and extra-articular manifestations such as rheumatoid nodules, lung involvement, or vasculitis.	Uncontrolled RA damages more than joints.
14	What is the significance of achieving remission in RA?	Remission reduces joint damage, preserves function, and improves quality of life; it is the primary treatment goal.	Aim for 'zero' disease activity.
15	Describe the concept of 'treat-to-target' in RA management.	A strategy where treatment is adjusted regularly with the goal of reaching and maintaining remission or low disease activity.	Treat-to-target emphasizes proactive management.
16	What modifications are recommended for RA patients with comorbid cardiovascular disease?	Use of low-dose corticosteroids cautiously, control of lipid levels, encourage smoking cessation, and promote physical activity, all while managing RA effectively.	Manage both RA and CV risks simultaneously.
17	Name a key factor influencing the choice between conventional and biologic DMARDs.	Disease severity, response to prior therapy, presence of comorbidities, and patient preference.	Tailor therapy based on individual patient factors.
18	What is the significance of anti-CCP antibodies in RA?	Anti-cyclic citrullinated peptide (anti-CCP) antibodies are specific markers that predict more aggressive disease and joint damage.	Anti-CCP positivity indicates a more severe RA course.
19	How does patient adherence influence RA treatment outcomes?	High adherence improves disease control, reduces flare frequency, and prevents joint damage; non-adherence can lead to treatment failure.	Adherence is key to success.
20	What is the typical first-line biologic agent used in RA?	Tumor necrosis factor (TNF) inhibitors such as etanercept or infliximab are often first-line biologics.	TNF inhibitors are the 'go-to' biologics initially.

Note: This preview shows only the first 20 cards. The complete deck contains 22 total cards. Start studying to access all flashcards.

Master all 22 flashcards

More Flashcard Decks

Explore other decks you might find helpful

Preventive Eye Care and Public Health

32 cards

Emergency Eye Care and Trauma Management

29 cards

Cell Structure and Organelles

28 cards

Basic Plant Anatomy and Structure

28 cards